Share

    


Home / Search Results

Search Results

Search Publications

Search Again?

Filter By Content Type

Filter By Topic

In July 2022, the House of Representatives overwhelmingly passed the Advancing Telehealth Beyond COVID-19 Act (H.R. 4040) to extend Medicare telehealth flexibilities enacted during the COVID-19 public health emergency through December 31, 2024. ACCC joined 375 patient and provider stakeholder groups in encouraging the Senate to adopt similar legislation to ensure a two-year extension to these telehealth …
PowerPoint Presentation Sept. 8, 2022 TxSCO Update Overview: Notable Updates 2 Federal • Surprise Billing • Inflation Reduction Act State • Legislative hearing on health care workforce • State general election updates Federal Update No Surprises Act: Timeline 4 December 27, 2020 • No Surprises Act (NSA) signed into law …
Accelerated Approvals Reconsidered Tabrecta® (capmatinib hydrochloride) – Novartis was notified that the accelerated approval it had received for use of its kinase inhibitor for treating adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping (as detected by an FDA-approved test) has …
Accelerated Approvals Reconsidered Tabrecta® (capmatinib hydrochloride) – Novartis was notified that the accelerated approval it had received for use of its kinase inhibitor for treating adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping (as detected by an FDA-approved test) has …
Accelerated Approvals Reconsidered Tabrecta® (capmatinib hydrochloride) – Novartis was notified that the accelerated approval it had received for use of its kinase inhibitor for treating adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping (as detected by an FDA-approved test) has …
Rockville, MD—September marks Ovarian Cancer Awareness Month, and in the U.S., it is estimated that 19,880 women will be diagnosed with ovarian cancer in 2022, and 12,810 women will die from the disease this year. The Association of Community Cancer Centers (ACCC) is offering two Ovarian Cancer Education initiatives, directed at oncology care programs across the country, to improve the delivery of …
Care of the adult with SCD Sickle Cell Disease in North Carolina 2022: An Optimistic Update. Jane Little, MD UNC Chapel Hill Jane_little@mail.unc.edu Disclosure of Conflicts of Interest Jane Little, MD, has the following financial relationships to disclose: • Inventor on Hemex and SCD Biochip Patent • Research support from Bluebird Bio • Research support from GBT • Adjudication …
The COVID-19 pandemic brought renewed attention to the concept of the home being a site of care. Looking to the future, certain strategies can be implemented for cancer programs aiming to offer care to patients in their homes.
F I N A N C I A L A D V O C AC Y N E T W O R K ASSOCIATION OF COMMUNITY CANCER CENTERS ACCC 2021 Financial Advocacy Network Summit What’s Ahead The Association of Community Cancer Centers (ACCC) Financial Advocacy Summit is an annual opportunity for members to con- nect and discuss the current and critical issues impacting financial advocacy. The Summit was held virtually in September …
This study examined the coping strategies and psychosocial well-being of patients with lung cancer facing multiple stressors, primarily due to the COVID-19 pandemic.
12 accc-cancer.org | Vol. 37, No. 5, 2022 | OI C oastal Cancer Center is a private oncology practice with four locations across South Carolina’s Grand Strand, bordering the Atlantic Ocean. Established in 1982, Coastal Cancer Center has been a pillar in its community for decades. In 2010, it was the first practice in the state to become Quality Oncology Practice Initiative certified. The …
A comparison between the Enhancing Oncology Model (EOM), and its predecessor, the Oncology Care Mode (OCM).
This program delivers intensive hospital-level care to eligible patients in their own homes through a care team that includes oncology nurse practitioners, home health registered nurses, and allied healthcare staff.
Home as a site of care for patients with cancer Association of Community Cancer Centers This publication is a benefit of membership Association of Community Cancer Centers Vol. 37 | No. 5 | 2022 Improving physical and metabolic health with a community-based program | 42 Bridging the sexual health communication gap in cancer care | 32 Implementing anti-cancer therapy …
Advanced Practice Providers able to sign anti-cancer therapy orders practice at the top of their license and can help free up physician time to see more new patients, streamline clinic workflows, and improve the patient experience.
Upper GI/Hepatobiliary Cancers CHANDRIKHA C HANDRASEKHARAN C LINICAL A SSOCIATE PROFESSOR UNIVERSITY O F IOWA Disclosure of Conflicts of Interest Chandrikha Chandrasekharan, MD has the following financial relationship to disclose: Research funding - AstraZeneca ASCO 2022 updates in GEJ/Gastric cancers and Hepatobiliary cancers Permissions Dr. Chandrasekharan …
68 accc-cancer.org | Vol. 37, No. 5, 2022 | OI ACCC Welcomes Its Newest Members CHRISTUS Trinity Mother Frances Oncology Institute Tyler, Tex. Delegate Rep: Stephanie Thomas, MBA, MSN Website: christushealth.org/locations/oncology-institute Coastal Cancer Center Myrtle Beach, S.C. Delegate Rep: Emily Touloukian, MD Website: coastalcancercenter.com Dell Children’s Blood and Cancer Center of …
Home as a site of care for patients with cancer Association of Community Cancer Centers This publication is a benefit of membership Association of Community Cancer Centers Vol. 37 | No. 5 | 2022 Improving physical and metabolic health with a community-based program | 42 Bridging the sexual health communication gap in cancer care | 32 Implementing anti-cancer therapy …
14 accc-cancer.org | Vol. 37, No. 5, 2022 | OI Approved Drugs • On June 24 the U.S. Food and Drug Administration (FDA) approved Breyanzi® (lisocabtagene maraleucel) (Bristol Myers Squibb, bms.com) for adult patients with large B-cell lymphoma who have refractory disease to first-line chemo- immunotherapy or relapse within 12 months of first-line chemo- immunotherapy or who have refractory …
Advancements in reproductive science has provided more options for women to take greater control of their reproductive future.